Bugatinib 90mg Brigatinib tablets 90mg x 30 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Interstitial lung disease (ILD)/pneumonia: Monitor for new or worsening respiratory symptoms, especially during the first week of treatment. In case of new or worsening respiratory symptoms, LuciBriga should be interrupted and ILD/pneumonia should be assessed immediately. After recovery, reduce the dose or permanently discontinue LuciBriga.
• Blood Pressure: Blood pressure is monitored after 2 weeks and then at least monthly during treatment. For severe blood pressure, interrupt LuciBriga and then reduce the dose or permanently discontinue.
• Bradycardia: Monitor heart rate and blood pressure regularly during treatment. If symptomatic, interrupt LuciBriga and then reduce the dose or permanently discontinue.
• Visual impairment: Patients are advised to report visual symptoms. Discontinue LuciBriga and perform an ophthalmic evaluation, then reduce the dose or permanently discontinue LuciBriga.
• Elevated creatine phosphokinase (CPK): CPK levels are regularly monitored during treatment. Suspend LuciBriga depending on severity and muscle pain or weakness, then resume or reduce dose.
• Elevated pancreatic enzymes: Lipase and amylase levels are regularly monitored during treatment. Depending on the severity, interrupt LuciBriga and resume or reduce the dose.
• Hepatotoxicity: Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin levels are regularly monitored during treatment. Depending on the severity, the dose was interrupted and then resumed at a lower level.
• Hyperglycemia: Fasting blood glucose is regularly assessed before and during treatment with LuciBriga. If not adequately controlled by optimal medical management, interrupt LuciBriga and consider dose reduction or permanent discontinuation, depending on the severity.
• Photosensitivity: Patients are advised to limit sun exposure. Discontinue LuciBriga according to severity and resume, reduce, or permanently discontinue at the same dose.
• Embryo-fetal toxicity: May cause harm to the fetus. Women of childbearing potential are advised to be aware of the potential risks to the fetus and to use effective contraception.

Medication risks

Adverse Reactions
The most common adverse effects (≥ 25%) of LuciBriga are diarrhea, fatigue, nausea, rash, cough, myalgia, headache, Blood Pressure, vomiting, and difficulty breathing.